| Literature DB >> 35449650 |
Leonard Simoni1, Ilir Alimehmeti2, Astrit Ceka1, Mirald Gina1, Ermir Tafaj1, Alban Dibra1, Artan Goda1.
Abstract
Background The incidence of acute coronary syndromes (ACS) decreased during the coronavirus disease 2019 (COVID-19) pandemic. Few studies have investigated gender differences in ACS admissions and outcomes during pandemics and have presented divergent results. This study aimed to investigate the effect of the COVID-19 pandemic on male and female hospitalizations and in-hospital outcomes in patients presenting with ACS. Methodology We designed a retrograde, single-center trial gathering data for ACS hospitalizations during the lockdown (March 9, 2020, to April 30, 2020) compared with the same timeframe of 2019. ACS hospitalizations were subgrouped as ST-elevation myocardial infarction (STEMI), non-STEMI (NSTEMI), and unstable angina (UA). We calculated the incidence rate ratio (IRR) to compare all-ACS and subgroups for male and female hospitalizations and the risk ratio (RR) to compare overall male/female mortality. Results This study included 321 ACS patients (238 males, 83 females) during the COVID-19 lockdown and 550 patients (400 males, 150 females) during 2019. The IRRs of all-ACS/males/females were significantly lower during the COVID-19 period at 0.58 (95% confidence interval (CI) = 0.44-0.76), 0.59 (95% CI = 0.43-0.75), and 0.55 (95% CI = 0.37-0.74), respectively. The IRR for STEMI was significantly lower among females (0.59 (95% CI = 0.39-0.89)), but not among males (0.76 (95% CI = 0.55-1.08)) The IRR for NSTEMI was not significantly lower, meanwhile it was significantly lower for UA among both males and females. The overall ACS mortality increased during the COVID-19 period (7.4% vs. 3.4%; RR = 2.16 (95% CI = 1.20-3.89)). Important increase was found in males (7.45% vs. 2.5%; RR = 3.02 (95% CI = 1.42-6.44)), but not in females (7.2% vs. 6%; RR = 1.20 (95% CI = 0.44-3.27). Conclusions The admissions of ACS reduced similarly in males and females during the COVID-19 pandemic. The admissions of STEMI reduced predominantly in females. We identified a substantial increase in the overall ACS mortality, but predominantly in males, reducing the differences between males and females. Further studies are necessary to better understand the increase in male mortality during the pandemic.Entities:
Keywords: acute coronary syndromes; covid-19 pandemic; gender differences; hospitalizations; in-hospital outcomes
Year: 2022 PMID: 35449650 PMCID: PMC9013470 DOI: 10.7759/cureus.23286
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Baseline demographic, clinical, and procedural characteristics of the study population according to gender groups.
*To determine statistical significance continuous variables were presented as mean ± SD and compared using t-tests; meanwhile, categorical variables were presented as percentages compared using the chi-square test.
STEMI: ST‐segment elevation myocardial infarction; CAD: coronary artery disease; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; CMP: cardiomyopathy; LM: left main; LAD: left anterior descending; LCx: left circumflex; RCA: right coronary artery
| Variables | Study period, Male 238 patients n (%) | Control period, Male 400 patients n(%) | P-value* | Study period, Female 83 patients n (%) | Control period, Female 150 patients n (%) | P-value* |
| Age, years (SD) | 64.54 (10.39) | 64.82 (10.64) | 0.864 | 67.80(10.52) | 69.15 (10.15) | 0.338 |
| STEMI | 121 (50.8%) | 158 (39.5%) | 0.007 | 35 (42.2%) | 59 (39.3%) | 0.777 |
| NSTEMI | 49 (20.6%) | 70 (17.5%) | 0.388 | 15 (18.1%) | 25 (16.7%) | 0.927 |
| UA | 68 (28.6%) | 172 (43%) | <0.001 | 33 (39.7%) | 66 (44%) | 0.625 |
| Diabetes mellitus | 100 (42.1%) | 163 (40.8%) | 0.817 | 36(43.4%) | 82 (54.7%) | 0.130 |
| Hypertension | 213 (89.5%) | 363 (90.8%) | 0.705 | 79 (95.2%) | 139 (92.7%) | 0.638 |
| Dyslipidema | 132 (55.5%) | 208 (52%) | 0.444 | 47 (56.6%) | 82 (54.7%) | 0.880 |
| Smoking | 89 (37.4%) | 159 (39.8%) | 0.613 | 3 (3.6%) | 14 (9.3%) | 0.179 |
| Previous CAD | 44 (18.5%) | 99 (24.8%) | 0.082 | 9 (10.8%) | 34 (22.7%) | 0.032 |
| Dilated CMP | 8 (3.8%) | 35 (8.8%) | 0.014 | 4 (4.8%) | 10 (6.7%) | 0.779 |
| Impaired renal function | 37 (15.6%) | 49 (12.3%) | 0.289 | 6 (7.2%) | 22 (14.7%) | 0.143 |
| Previous stroke | 9 (3.8%) | 17 (4.3%) | 0.934 | 2 (2.4%) | 9 (6.0%) | 0.360 |
| Coronary angiography | 214 (89.9%) | 369 (92.3%) | 0.384 | 69 (83.1%) | 127 (84.7%) | 0.904 |
| Refused coronary-angiography | 17 (7.1%) | 21 (5.3%) | 0.421 | 13 (15.7%) | 17 (11.3%) | 0.453 |
| CAD (n % angiography.) | 202 (94.4%) | 331 (90.0%) | 0. 072 | 53 (76.8%) | 106 (83.5%) | 0.344 |
| One-vessel CAD (n % angiography) | 54 (25.2%) | 85 (23%) | 0.617 | 18 (26.1%) | 34(26.7%) | 0.945 |
| Two-vessel CAD (n % angiography) | 49 (22.9%) | 123 (33.3%) | 0.010 | 19 (27.5%) | 30 (23.6%) | 0.665 |
| Three-vessel CAD (n % angiography) | 99 (46.3%) | 123 (33.3%) | 0.003 | 16 (23.2%) | 42 (33.1%) | 0.199 |
| LM disease (n % angiography) | 31 (14.5%) | 36 (9%) | 0. 141 | 6 (8.7%) | 6 (4.7%) | 0.448 |
| No critic stenoses (n % angiography) | 12 (5.6%) | 38 (9.8%) | 0.127 | 16(23.2%) | 21(16.5%) | 0.385 |
| PCI (% patients) | 135 (63.1%) | 223 (60.4%) | 0.585 | 40 (58.0%) | 80 (63.0%) | 0.592 |
| PCI of LAD (% of PCI) | 78 (57.8%) | 128 (57.4%) | 0.944 | 27 (67.5%) | 55 (68.5%) | 0.845 |
| PCI of LCX (% of PCI) | 37 (27.4%) | 62 (27.8%) | 0.941 | 10 (25.0%) | 21 (26.3%) | 0.890 |
| PCI of RCA (% of PCI) | 57 (42.2%) | 101 (45.3%) | 0.674 | 12 (30%) | 34 (42.5%) | 0.231 |
| CABG recommended (% patients) | 51(21.2%) | 81 (20.3%) | 0.673 | 9 (13%) | 16 (12.6%) | 0.930 |
| CABG performed (% patients) | 20 (9.3%) | 24 (6%) | 0.276 | 3 (3.3%) | 6 (4.7%) | 0.904 |
| CAD with medical treatment (n % patients) | 17 (7.9%) | 36 (9.8%) | 0.559 | 8 (11.6%) | 16 (12.6%) | 0.838 |
Figure 1Gender-related coronary syndrome admissions during the COVID-19 and control periods.
Male and female all-ACS, STEMI, non‐STEMI, and UA admissions during the COVID-19 period (red bars) and control period (blue bar) showing the percentage reduction and statistical significance.
ACS: acute coronary syndrome; STEMI: ST‐segment elevation myocardial infarction; UA: unstable angina; COVID-19: coronavirus disease 2019
Figure 2All/male/female ACS admissions difference percentage between the COVID-19 and control periods.
The weekly admission difference percentage between the lockdown and control periods was obtained for all-ACS, showing an important reduction in all/male/female admissions during the second to the fifth week of the study compared to the control period.
ACS: acute coronary syndromes; COVID-19: coronavirus disease 2019
The incidence rate ratio of male/female admissions and invasive procedures.
†IRR for admissions and invasive procedures obtained from the analyses of seven weeks during the lockdown and control periods presented as IRR and 95% CI.
STEMI: ST‐segment elevation myocardial infarction; PCI: percutaneous coronary intervention; IRR: incidence rate ratio; CI: confidence interval
*To determine statistical significance for the comparison regarding male/female ACS and subgroups admissions and procedures, the Poisson regression (admissions/procedure per week model) was used.
| Admission presentation and procedures | COVID‐19 | Control | IRR IRR (95% CI)† | P‐value* |
| ACS males (% all patients) | 238 (74%) | 400 (73%) | 0.60 (0.43-0.75) | <0.001 |
| ACS females (% all patients) | 83 ( 26%) | 150 (27%) | 0.55 (0.37-0.77) | 0.001 |
| STEMI males (% all males) | 121 (50.8%) | 158 (39.5%) | 0.77 (0.55-1.07) | 0.131 |
| STEMI females (% all females) | 35 (42.2%) | 59 (39.3%) | 0.59 (0.39-0.89) | 0.013 |
| NSTEMI males (% all males) | 49 (20.6%) | 70 (17.5%) | 0.70 (0.36-1.19) | 0.452 |
| NSTEMI females (% all females) | 15 (18.1%) | 25 (16.7%) | 0.60 (0.27-1.10) | 0.360 |
| UA males (% all males) | 68 (28.6%) | 172 (43%) | 0.39 (0.23-0.51) | <0.001 |
| UA females (% all females) | 33 (39.7%) | 66 (44%) | 0.55 (0.33-0.84) | 0.001 |
| Angiography males | 214 (89.9%) | 369 (92.3%) | 0.58 (0.43-0.76) | 0.009 |
| Angiography females | 69 (83.1%) | 127 (84.7%) | 0.54 (0.38-0.74) | 0.007 |
| PCI males | 135 (63.1%) | 223 (60.4%) | 0.61 (0.39-0.90) | 0.031 |
| PCI females | 40 (58.0%) | 80 (63.0%) | 0.50 (0.31-0.78) | 0.002 |
Male and female in-hospital outcomes between the study and control periods.
*To determine statistical significance for the comparison regarding each in-hospital outcome variable were summarized using mean ± SD for continuous variables compared using t-test and frequency and percentage for categorical variables compared using the chi-square test.
ACS: acute coronary syndrome; ICU: intensive care unit; cTn I: cardiac Troponin I
| Variables | Study period, Male 238 patients n (%) | Control period, Male 400 patients n (%) | P-value* | Study period, Female 83 patients n (%) | Control period, Female 150 patients n (%) | P value* |
| Symptom onset-ICU time (SD) (hours) | 14.54 (17.94) | 7.08 (5.88) | <0.001 | 19.76 (21.05) | 7.79 (7.63) | <0.001 |
| ICU-sheath time (SD) (minutes) | 47.8 (24.4) | 57.8 (33.42) | 0.011 | 54.7 (42.5) | 55.0 (33.2) | 0.964 |
| cTn I (SD) | 21.01 (45.11) | 9.01 (24.65) | <0.001 | 18.64 (38.53) | 15.45 (52.58) | 0.653 |
| Ejection fraction (SD) | 48.24 (11.68) | 50.68 (11.33) | 0.010 | 49.01 (13.40) | 51.65 (12.40) | 0.132 |
| Length of stay (SD) | 4.29 (2.49) | 6.52 (3.40) | <0.001 | 4.95 (3.65) | 6.94 (3.70) | <0.001 |
| Death | 18 (7.6%) | 10 (2.5%) | 0.005 | 6 (7.2%) | 9 (6.0%) | 0.783 |
| Cardiogenic shock | 29 (12.2%) | 16 (4.0%) | <0.001 | 13 (15.7%) | 12 (8.0%) | 0.112 |
Overall/male/female major complications risk ratios.
†RR for death and CSH was obtained from the comparison of event rate (death/CSH) between the lockdown and control periods and expressed as RR and 95% CI.
CSH: cardiogenic shock; RR: risk ratio; CI: confidence interval
| Complications | COVID‐19 | Control | RR (95% CI)† | P‐value |
| Death n (% all patients) | 24 (%) | 19 (%) | 2.16 (1.20-3.89) | 0.001 |
| Death males | 18 (7.6%) | 10 (2.5%) | 3.02 (1.42-6.44) | 0.004 |
| Death females | 6 (7.2%) | 9 (6.0%) | 1.20 (0.44-3.27) | 0.714 |
| CSH n (% all patients) | 42 (21.2%) | 28 (12.4%) | 2.57 (1.63-4.06) | <0.001 |
| CSH males | 29 | 16 | 3.05 (1.69-5.49) | <0.001 |
| CSH females | 13 | 12 | 1.96 (0.94-4.09) | 0.074 |
Study and control in-hospital outcomes between males and females.
*To determine statistical significance variables were summarized using mean ± SD for continuous variables compared using t-tests, and percentages for categorical variables were compared using chi-square tests.
ACS: acute coronary syndrome; ICU: intensive care unit; cTn I: cardiac Troponin I; SD: standard deviation
| Variables | Study period, Male 238 patients n (%) | Study period, Female 83 patients n (%) | P-value* | Control period, Male 400 patients n (%) | Control period, Female 150 patients n (%) | P-value* |
| Symptom onset-ICU time (SD), hours | 14.54 (17.94) | 19.76 (21.05) | 0.08 | 7.08 (5.88) | 7.79 (7.63) | 0.673 |
| cTn I (SD) | 21.01 (45.11) | 18.64 (38.53) | 0.235 | 9.01 (24.65) | 15.45 (52.58) | 0.452 |
| Ejection fraction (SD) | 48.24 (11.68) | 49.01 (13.40) | 0.620 | 50.68 (11.33) | 51.65 (12.40) | 0.383 |
| Death | 18 (7.6%) | 6 (7.2%) | 0.891 | 10 (2.5%) | 9 (6.0%) | 0.015 |
| Cardiogenic shock | 29 (12.2%) | 13 (15.7%) | 0.672 | 16 (4.0%) | 12 (8.0%) | 0.112 |